When most people hear about GLP-1 medications such as semaglutide or tirzepatide, they immediately think about weight loss.
But weight reduction is only part of the story.
Research over the past several years has shown that medications affecting the GLP-1 pathway may have important effects on cardiovascular health, blood sugar, kidney disease, liver disease, sleep apnea and other obesity-related conditions.
In fact, some GLP-1–based medications now have FDA-approved indications that extend well beyond weight management.
Here are seven important potential health benefits worth knowing about.
1. GLP-1 Medications May Help Protect the Heart
One of the strongest areas of evidence involves cardiovascular health.
The large SELECT clinical trial studied more than 17,000 adults who had cardiovascular disease and overweight or obesity but did not have diabetes.
Participants receiving semaglutide 2.4 mg had a 20% lower relative risk of major cardiovascular events—cardiovascular death, nonfatal heart attack or nonfatal stroke—compared with participants receiving placebo.
These findings were significant enough that the FDA approved Wegovy® (semaglutide) to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and either obesity or overweight.
This is an important change in how GLP-1 therapy is viewed. For appropriately selected patients, treatment may involve much more than a number on the scale.
2. Some GLP-1 Medications May Help Protect Kidney Function
The kidneys are another area where compelling evidence has emerged.
The FLOW trial examined semaglutide in people with type 2 diabetes and chronic kidney disease.
Semaglutide reduced the risk of clinically important kidney outcomes and cardiovascular death. Kidney function also declined more slowly among participants receiving semaglutide.
The evidence led the FDA to approve an additional indication for Ozempic® (semaglutide): reducing the risk of sustained kidney-function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
For patients who have both diabetes and kidney disease, this can be an especially important consideration when discussing treatment options with a healthcare professional.
3. GLP-1 Therapy May Improve MASH and Liver Health
Another major development involves metabolic dysfunction-associated steatotic liver disease (MASLD) and its more serious inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH).
MASH can cause ongoing liver inflammation and fibrosis, eventually progressing to cirrhosis and other serious complications.
In the phase 3 ESSENCE trial, semaglutide improved liver histology in patients with MASH and moderate or advanced fibrosis.
The FDA subsequently approved Wegovy for treatment of noncirrhotic MASH in adults with moderate-to-advanced liver fibrosis.
In the interim clinical trial analysis cited by the FDA, 63% of patients receiving Wegovy achieved resolution of MASH without worsening of liver fibrosis, compared with 34% receiving placebo.
Improvement in fibrosis without worsening of MASH occurred in 37% of Wegovy-treated patients compared with 22% receiving placebo.
This indication was granted under accelerated approval, and the ongoing trial is evaluating whether these improvements ultimately translate into fewer major liver-related clinical events.
4. Tirzepatide Can Improve Obstructive Sleep Apnea in Certain Patients
Obstructive sleep apnea, or OSA, is another condition closely associated with obesity.
In December 2024, the FDA approved Zepbound® (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, along with reduced-calorie nutrition and increased physical activity.
The approval followed randomized clinical trials showing meaningful reductions in the apnea-hypopnea index, or AHI—the number of apnea and hypopnea events occurring during sleep.
Some patients experienced enough improvement to reach remission or mild sleep apnea with resolution of symptoms.
This does not mean everyone with sleep apnea should stop CPAP or another prescribed therapy. Treatment decisions should be made with the patient’s healthcare provider.
However, the evidence demonstrates an important connection between metabolic treatment and sleep-related breathing disorders.
5. GLP-1–Based Treatment May Improve Certain Forms of Heart Failure
Researchers are also examining how GLP-1–based therapies affect heart failure, particularly heart failure with preserved ejection fraction (HFpEF) associated with obesity.
The SUMMIT trial studied 731 patients with obesity and HFpEF.
A cardiovascular-death or worsening-heart-failure event occurred in 9.9% of participants receiving tirzepatide compared with 15.3% receiving placebo.
Patients receiving tirzepatide also experienced improvements in health status and symptoms.
These results suggest that treating obesity and metabolic dysfunction may have important effects on how certain patients with heart failure feel and function.
6. GLP-1 Medications Improve Blood Sugar and Metabolic Health
GLP-1 receptor agonists were being used to treat type 2 diabetes long before they became widely known for weight loss.
GLP-1 signaling can help stimulate insulin release when blood glucose is elevated, reduce inappropriate glucagon secretion, slow gastric emptying and influence appetite and food intake.
For people with type 2 diabetes, these effects can significantly improve glucose control.
Better metabolic health can also influence several interconnected risk factors, including blood pressure, waist circumference and other markers associated with cardiometabolic disease.
This is one reason healthcare professionals increasingly look at obesity, diabetes, cardiovascular disease, kidney disease and liver disease as interconnected metabolic conditions rather than completely separate problems.
7. Researchers Are Studying Broader Anti-Inflammatory and Metabolic Effects
Perhaps the most interesting question is what comes next.
Researchers are investigating whether GLP-1–based medications influence inflammatory pathways and other biological processes beyond their effects on appetite and body weight.
There is growing scientific interest in possible applications involving cardiovascular inflammation, metabolic disease and other chronic conditions.
However, it is important to distinguish between established benefits and promising research.
A medication should not be assumed to prevent or treat a disease simply because early studies suggest a biological effect. Large randomized clinical trials and FDA review remain important for determining whether a potential benefit is clinically meaningful.
Are the Benefits Simply From Losing Weight?
Not necessarily—but the answer is complicated.
Losing excess weight itself can improve blood pressure, insulin resistance, sleep apnea, fatty liver disease, mobility and cardiovascular risk.
Therefore, some benefits observed during GLP-1 treatment are likely related to weight reduction.
Researchers are also investigating whether GLP-1 receptor activation produces beneficial effects that are partially independent of weight loss.
The safest conclusion is that GLP-1–based treatment can affect multiple interconnected metabolic systems, and scientists are still determining exactly how much of each benefit results directly from weight reduction versus other biological mechanisms.
GLP-1 Medications Are Becoming More Than “Weight-Loss Drugs”
The science surrounding GLP-1 medications has changed considerably.
These medications should no longer be thought of solely as treatments designed to help someone lose pounds.
Depending on the specific medication and patient, GLP-1–based treatment may also play a role in:
- Cardiovascular risk reduction
- Type 2 diabetes management
- Chronic kidney disease
- MASH and metabolic liver disease
- Obstructive sleep apnea
- Certain obesity-related heart-failure conditions
Importantly, these benefits do not apply equally to every GLP-1 medication or every patient. FDA indications differ among semaglutide, tirzepatide and other medications in this class.
Could GLP-1 Therapy Be Right for You?
The best treatment depends on much more than body weight.
A healthcare professional may consider your medical history, current medications, BMI, cardiovascular health, blood sugar, kidney function, liver health, sleep apnea and other risk factors before determining whether GLP-1 therapy is appropriate.
At DPC Medical – Dodson Pain Consultants, we believe weight management should focus on improving overall health—not simply changing the number on the scale.
If you are interested in medically supervised GLP-1 weight-management therapy, contact DPC Medical to learn more and determine whether treatment may be appropriate for you.
This article is for educational purposes only and does not replace individualized medical advice, diagnosis or treatment. GLP-1 and GLP-1/GIP medications have specific indications, contraindications, warnings and potential adverse effects. Individual results vary.
For more information on GLP-1 medication, please see this link. Medicare’s new GLP-1 Bridge Program.
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563.
- U.S. Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. March 8, 2024.
- Perkovic V, Tuttle KR, Rossing P, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024. doi:10.1056/NEJMoa2403347.
- U.S. Food and Drug Administration. Ozempic (semaglutide) supplemental approval: indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. 2025.
- Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-2099. doi:10.1056/NEJMoa2413258.
- U.S. Food and Drug Administration. FDA approves treatment for serious liver disease known as “MASH.” August 15, 2025.
- U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. December 20, 2024.
- Packer M, Zile MR, Kramer CM, et al.; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392:427-437. doi:10.1056/NEJMoa2410027.